Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus ZYRTEC HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE HYDROCHLORIDE versus ZYRTEC HIVES.
LEVOCETIRIZINE HYDROCHLORIDE vs ZYRTEC HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective peripheral histamine H1-receptor antagonist. It inhibits the effects of histamine at the H1 receptor, reducing allergic symptoms such as itching, sneezing, and rhinorrhea. It has lower affinity for central H1 receptors and anticholinergic properties compared to first-generation antihistamines.
Selective histamine H1-receptor antagonist. Inhibits histamine-mediated vasodilation, capillary permeability, and smooth muscle contraction.
Oral, 5 mg once daily in the evening.
For chronic idiopathic urticaria, adults: 10 mg orally once daily. For intermittent symptoms, up to 10 mg once daily as needed.
None Documented
None Documented
Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 20–24 hours in renal impairment (CrCl <40 mL/min); clinically, stable levels require 2–3 days.
The terminal elimination half-life is approximately 8.3 hours in healthy adults. In patients with renal impairment (CrCl < 40 mL/min), half-life can extend to 18–21 hours, necessitating dose adjustment.
Approximately 85% renal excretion as unchanged drug via glomerular filtration and tubular secretion, 12.9% fecal excretion, <1% biliary.
Cetirizine is primarily excreted renally as unchanged drug (approximately 70%). Fecal excretion accounts for about 10%. The remainder undergoes hepatic metabolism to inactive metabolites, which are also renally eliminated.
Category A/B
Category C
Antihistamine
Antihistamine